anti- Noggin antibody

Contáctenos para saber el precio
Por favor contáctenos para obtener información detallada sobre el precio y disponibilidad.
935106861
info@markelab.com
name
anti- Noggin antibody
category
Primary Antibodies
provider
FineTest
reference
FNab05782
tested applications
ELISA, WB, IHC
Documents del producto
Instrucciones
Data sheet
Product specifications
Category | Primary Antibodies |
Immunogen Target | noggin |
Host | Rabbit |
Reactivity | human,mouse,rat |
Recommended Dilution | WB: 1:500-1:2000; IHC: 1:20-1:200 |
Clonality | polyclonal |
Conjugation | Unconjugated |
Isotype | IgG |
Observed MW | 26 kDa |
Purity | ≥95% as determined by SDS-PAGE |
Purification | Immunogen affinity purified |
Size 1 | 100µg |
Form | liquid |
Tested Applications | ELISA, WB, IHC |
Storage | PBS with 0.02% sodium azide and 50% glycerol pH 7.3,-20℃ for 12 months(Avoid repeated freeze / thaw cycles.) |
UniProt ID | Q13253 |
Alias | SYM1, SYNS1,SYNS1A |
Background | Antibody anti-NOG |
Status | RUO |
Note | This product is for research use only. |
Noggin (NOG) is a secreted glycoprotein that plays a critical role in regulating embryonic development and tissue homeostasis. It functions as an antagonist of bone morphogenetic proteins (BMPs), members of the transforming growth factor-beta (TGF-β) superfamily. By binding directly to BMPs such as BMP-2, BMP-4, and BMP-7, Noggin inhibits their ability to interact with receptors on the cell surface, thereby preventing the activation of downstream signaling pathways. This modulation is essential for proper skeletal development, including joint formation and bone growth, as well as the differentiation of neural and mesenchymal tissues. Noggin is expressed in various embryonic structures, including the notochord and somites, and its spatial and temporal expression is tightly regulated to ensure normal development. Mutations or dysregulation of NOG can result in skeletal disorders such as symphalangism and multiple synostoses syndrome. Noggin has also been implicated in processes like wound healing, cancer, and fibrosis, where BMP signaling plays a role. As a therapeutic target, Noggin's ability to modulate BMP activity makes it a potential candidate for treating conditions like osteoporosis and fibrodysplasia ossificans progressiva (FOP). Its role in tissue engineering and regenerative medicine is also being explored.